1. Nicotiana tabacum L. USDA, NRCS. 2007. The PLANTS Database ( http://plants.usda.gov , February, 2010). National Plant Data Center, Baton Rouge, LA 70874-4490 USA.
2. Hatsukami DK, Ebbert JO, Feuer RM, Stepanov I, Hecht SS. Changing smokeless tobacco products new tobacco-delivery systems. Am J Prev Med . 2007;33(suppl 6):S368-S378. PubMed
3. Grasso P, Mann AH. Smokeless tobacco and oral cancer: an assessment of evidence derived from laboratory animals. Food Chem Toxicol . 1998;36(11):1015-1029. PubMed
4. National Toxicology Program. Smokeless tobacco. Rep Carcinog . 2002;10:236-238. PubMed
5. Brunnemann KD, Qi J, Hoffmann D. Chemical profile of two types of oral snuff tobacco. Food Chem Toxicol . 2002;40(11):1699-1703. PubMed
6. Nilsson R. A qualitative and quantitative risk assessment of snuff dipping. [published correction appears in Regul Toxicol Pharmacol . 1999;29(1):97]. Regul Toxicol Pharmacol . 1998;28(1):1-16. PubMed
7. Djordjevic MV, Doran KA. Nicotine content and delivery across tobacco products. Handb Exp Pharmacol . 2009;(192):61-82. PubMed
8. Kotlyar M, Mendoza-Baumgart MI, Li ZZ, et al. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. Tob Control . 2007;16(2):138-142. PubMed
9. Melikian AA, Hoffmann D. Smokeless tobacco: a gateway to smoking or a way away from smoking. Biomarkers . 2009;14(suppl 1):85-89. PubMed
10. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol . 2008;9(7):667-675. PubMed
11. Timberlake DS, Zell JA. Review of epidemiologic data on the debate over smokeless tobacco's role in harm reduction. BMC Med . 2009;7:61. PubMed
12. Tomar SL, Fox BJ, Severson HH. Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking? Int J Environ Res Public Health . 2009;6(1):10-24. PubMed
13. NIH State-of-the-Science Panel. National Institutes of Health State-of-the-Science conference statement: tobacco use: prevention, cessation, and control. Ann Intern Med . 2006;145(11):839-844. PubMed
14. Tilashalski K, Rodu B, Cole P. Seven year follow-up of smoking cessation with smokeless tobacco. J Psychoactive Drugs . 2005;37(1):105-108. PubMed
15. T⊘nnesen P, Mikkelsen K, Bremann L. Smoking cessation with smokeless tobacco and group therapy: an open, randomized, controlled trial. Nicotine Tob Res . 2008;10(8):1365-1372. PubMed
16. Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Med . 2009;7:36. PubMed
17. Stellman SD, Djordjevic MV. Monitoring the tobacco use epidemic II: The agent: Current and emerging tobacco products. Prev Med . 2009;48(suppl 1):S11-S15. PubMed
18. Russell MA, Jarvis MJ, Feyerabend C. A new age for snuff? Lancet . 1980;1(8166):474-475. PubMed
19. England LJ, Levine RJ, Mills JL, Klebanoff MA, Yu KF, Cnattingius S. Adverse pregnancy outcomes in snuff users. Am J Obstet Gynecol . 2003;189(4):939-943. PubMed
20. Gupta PC, Subramoney S. Smokeless tobacco use, birth weight, and gestational age: population based, prospective cohort study of 1217 women in Mumbai, India. [published correction appears in BMJ . 2010;340:c2191]. BMJ . 2004;328(7455):1538. PubMed
21. Rogers JM. Tobacco and pregnancy. Reprod Toxicol . 2009;28(2):152-160. PubMed
22. Rogers JM. Tobacco and pregnancy: overview of exposures and effects. Birth Defects Res C Embryo Today . 2008;84(1):1-15. PubMed
23. Kuykendall JR, Houle MD, Rhodes RS. Possible warfarin failure due to interaction with smokeless tobacco. Ann Pharmacother . 2004;38(4):595-597. PubMed
24. Asplund K. Smokeless tobacco and cardiovascular disease. Prog Cardiovasc Dis . 2003;45(5):383-394. PubMed
25. Pyles ST, Van Voris LP, Lotspeich FJ, McCarty SA. Sugar in chewing tobacco. N Engl J Med . 1981;304(6):365. PubMed
26. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ . 2009;339:b3060. PubMed
27. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax . 2003;58(5):435-443. PubMed
28. Hecht SS, Carmella SG, Edmonds A, et al. Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco. Tob Control . 2008;17(2):128-131. PubMed
29. Ebbert JO, Montori V, Vickers KS, Erwin PC, Dale LC, Stead LF. Interventions for smokeless tobacco use cessation. Cochrane Database Syst Rev . 2007;(4):CD004306. PubMed
30. Severson HH, Peterson AL, Andrews JA, et al. Smokeless tobacco cessation in military personnel: a randomized controlled trial. Nicotine Tob Res . 2009;11(6):730-738. PubMed
31. Boyle RG, Enstad C, Asche SE, et al. A randomized controlled trial of Telephone Counseling with smokeless tobacco users: the ChewFree Minnesota study. Nicotine Tob Res . 2008;10(9):1433-1440. PubMed
32. Danaher BG, Smolkowski K, Seeley JR, Severson HH. Mediators of a successful web-based smokeless tobacco cessation program. Addiction . 2008;103(10):1706-1712. PubMed
33. Severson HH, Gordon JS, Danaher BG, Akers L. ChewFree.com: evaluation of a Web-based cessation program for smokeless tobacco users. Nicotine Tob Res . 2008;10(2):381-391. PubMed
34. Ebbert JO, Dale LC, Severson H, et al. Nicotine lozenges for the treatment of smokeless tobacco use. Nicotine Tob Res . 2007;9(2):233-240. PubMed
35. Dale LC, Ebbert JO, Glover ED, et al. Bupropion SR for the treatment of smokeless tobacco use. Drug Alcohol Depend . 2007;90(1):56-63. PubMed
36. Accortt NA, Waterbor JW, Beall C, Howard G. Chronic disease mortality in a cohort of smokeless tobacco users. Am J Epidemiol . 2002;156(8):730-737. PubMed
37. Hatsukami DK, Lemmonds C, Tomar SL. Smokeless tobacco use: harm reduction or induction approach? Prev Med . 2004;38(3):309-317. PubMed
38. Warnakulasuriya KA, Ralhan R. Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco--a review. J Oral Pathol Med . 2007;36(2):63-77. PubMed
39. Critchley JA, Unal B. Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies. Eur J Cardiovasc Prev Rehabil . 2004;11(2):101-112. PubMed
40. Huhtasaari F, Lundberg V, Eliasson M, Janlert U, Asplund K. Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. J Am Coll Cardiol . 1999;34(6):1784-1790. PubMed
41. Asplund K, Nasic S, Janlert U, Stegmayr B. Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study. Stroke . 2003;34(7):1754-1759. PubMed
42. Taybos G. Oral changes associated with tobacco use. Am J Med Sci . 2003;326(4):179-182. PubMed